Margaret Moore, OD
Optometrist · Hamden, CTNPI 1760985915
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.8% of the total across 227 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 17.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,936, 7.6 times the $256 reported in 2019. Among optometrist clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 227 payments — averaging $30.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tarsus Pharmaceuticals, Inc.$1K
- Sun Pharmaceutical Industries Inc.$833
- Bausch & Lomb Americas Inc.$825
- Oyster Point Pharma, Inc.$630
- AbbVie$602
- Alcon$575
- plus $2K from 18 others
What the payments were for
- Food & beverage$6,71198%
- Gifts$391%
- Other$1122%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tarsus Pharmaceuticals, Inc. | 36 | $1,224 |
| Sun Pharmaceutical Industries Inc. | 31 | $833 |
| Bausch & Lomb Americas Inc. | 29 | $825 |
| Oyster Point Pharma, Inc. | 38 | $630 |
| AbbVie(2 entities) | 17 | $602 |
| Alcon | 12 | $575 |
| Harrow Eye, LLC | 23 | $401 |
| Dompe US, Inc. | 8 | $335 |
| Sight Sciences, Inc. | 4 | $291 |
| Ocular Therapeutix, Inc. | 2 | $258 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $161 |
| Carl Zeiss Meditec USA, Inc. | 2 | $112 |
| Apellis Pharmaceuticals, Inc. | 1 | $105 |
| Carl Zeiss Meditec, Inc. | 1 | $104 |
| Coopervision Inc. | 5 | $94 |
| Novartis | 3 | $71 |
| Amgen(2 entities) | 3 | $56 |
| Carl Zeiss Meditec AG | 2 | $39 |
| Johnson & Johnson Vision Care, Inc. | 2 | $38 |
| Biotissue Holdings Inc. | 1 | $33 |
| Kala Pharmaceuticals, Inc. | 1 | $22 |
| ABB Con-cise Optical Group LLC | 1 | $22 |
| Rayner Intraocular Lenses Limited | 1 | $18 |
| Tearlab Corp | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,863 in reported general payments places this provider in the 95th percentile of 574 optometrist providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 127 | $198,237 |
| XdemvyLotilaner | 55 | $102,261 |
| LumiganBimatoprost | 56 | $41,413 |
| CequaCyclosporine | 23 | $38,218 |
| XiidraLifitegrast | 19 | $36,301 |
| VevyeCyclosporine | 27 | $19,699 |
| MieboPerfluorohexyloctane/Pf | 25 | $18,549 |
| TyrvayaVarenicline Tartrate | 16 | $18,226 |
| Cyclosporine | 39 | $17,335 |
| RhopressaNetarsudil Mesylate | 22 | $13,149 |
| RocklatanNetarsudil Mesylat/Latanoprost | 30 | $11,891 |
| CombiganBrimonidine Tartrate/Timolol | 15 | $8,541 |
| VyzultaLatanoprostene Bunod | 15 | $7,532 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 36 | $5,314 |
| Latanoprost | 293 | $3,842 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $602 | $248,191198 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $1,224 | $102,26155 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $825 | $62,38259 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $833 | $38,21823 claims |
| Harrow Eye, LLCVevye | $401 | $19,69927 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $630 | $18,22616 claims |
| AlconSimbrinza | $575 | $3,05013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 574 optometrist providers in Connecticut.
Other optometrist in Hamden
- Joseph ThimonsFairfield$340K
- Inna LazarOld Greenwich$147K
- Jennifer StewartNew Canaan$91K
- Maria PribisStamford$78K
- Michael CooperWest Hartford$44K
- Joseph PavanoNew Britain$22K
- Susan JanikWest Hartford$20K
- Donald HigginsPlainville$18K
- Richard NowakEast Windsor$15K
- Barbara DuneHartford$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.